ADVERSEEVENTS CLOSES $2 MILLION SERIES A FINANCING

ADVERSEEVENTS CLOSES $2 MILLION SERIES A FINANCING

CUTTING EDGE DRUG SAFETY SCORING, SIGNALING, AND SIDE EFFECT

ANALYTICS PLATFORM SECURES FUNDING TO EXPAND ROLL-OUT

SANTA ROSA, CALIFORNIA, April 16, 2014… AdverseEvents Inc., a healthcare informatics company

focused on drug safety and side effects, today announced the closing of $2 Million in Series A financing

led by Evaluate Ltd., a market intelligence leader in consensus forecasts and analysis of the life science

industry.

The investment bolsters AdverseEvents' mission to make post-approval drug safety data accessible,

actionable, and predictable and affirms the strong demand for its drug scoring, signaling and side effect

analytics platform. The proceeds will be used to expand the company's sales force and analyst teams, and

to continue to build its marketing presence among health insurers, health systems and hospitals.

Other significant investors in this round include:

• Trevor Fenwick, founder and Executive Chairman of Euromonitor International, the global

information publisher.

• Michael Tansey, former president and CEO of Jobson, the healthcare information provider and

former CEO of the Scientific and Healthcare group at Thomson Reuters, the global information

provider.

In conjunction with the financing, Jonathan de Pass, the founder and CEO of Evaluate and Michael Tansey

will be joining AdverseEvents' board of directors.

AdverseEvents' CEO Brian Overstreet commented, "We are pleased to welcome Evaluate and our other

new investors to the company. Just as we have been deliberate in our build out of the company's core

technology and product offerings, we've been careful in choosing the right partners for our future growth.

All of our new investors and new board members have well established track records in healthcare and

life science intelligence and we are confident that the company will benefit greatly from their direct

involvement going forward."

Recognized for its game-changing analytical tools, AdverseEvents has become one of the foremost

research authorities on drug side effects – publishing comparative drug studies, industry white papers,

topical special reports, and platform validating research papers in leading academic journals.

Commenting on behalf of the investor group, Jonathan de Pass said, "AdverseEvents has identified a major

gap in healthcare information and has built a lasting solution that will have far reaching implications for all

of the industry's participants. We fully support Brian and his team in their goal of making drug safety data

actionable and look forward to working with AdverseEvents to help further penetrate the core healthcare

markets in the U.S. and globally.

 

The healthcare industry readily acknowledges the need for information that can drive improved patient

outcomes and lower avoidable medical costs. Studies put the systemic cost of drug side effects at $27

billion per year. But despite this huge cost burden and a well-known need for a solution, to date there

has been nothing offered in the market that can help improve patient outcomes and lower related costs.

AdverseEvents' proprietary technology, analytics, and product platform are positioned to disrupt the entire

post-approval drug industry with the broad roll out of its service offerings, primarily designed for health

insurers, health systems, hospitals, and related service providers.

About AdverseEvents, Inc.

AdverseEvents, Inc. (AEI) is a California-based healthcare informatics company that improves patient

safety and reduces systemic healthcare costs through the comprehensive analysis of post-marketing drug

side effect data. Utilizing data-mining and analysis technology, through its proprietary RxSuite™ of

analytics, AEI makes post-marketing drug safety data accessible, actionable, and predictable.

In addition to managed care organizations, AEI also provides services to enterprise markets including the

pharmaceutical industry and financial institutions. For more information visit: www.adverseevents.com.

On Twitter: @AdverseEvent.

Media Contact:

Sharon Miller

AdverseEvents, Inc.

+ 1 917-842-5378

[email protected]

About Evaluate Ltd.

Evaluate is the trusted source for life science market intelligence, with exclusive consensus forecasts

to 2020. We support life science and financial institutions, consultancies and service providers in their

strategic decision-making. Our services are EvaluatePharma, EvaluateClinicalTrials and EvaluateMedTech.

Our editorial team, EP Vantage, leverages our strategic analysis to provide daily opinion and forward-
looking insights. For more information visit: www.evaluategroup.com. On Twitter: @EvaluatePharma.

Evaluate Contact:

Christine Lindgren

Evaluate Ltd.

+1 617 573 9458

[email protected]

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.